Loading patent…
AssigneeIcahn School of Medicine at Mount Sinai
InventorsAdolfo GARCIA-SASTRE, Peter PALESE, Sara CUADRADO CASTAÑO
Estimating the term…
In one aspect, provided herein are naturally occurring and recombinantly produced avian paramyxovirus (APMV) (e.g., an APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9 strain) and uses of such APMV for the treatment of cancer. In particular, provided herein are methods for treating cancer comprising administering a naturally occurring or recombinantly produced APMV-4 strain to a subject in need thereof. In another aspect, provided herein are recombinant APMV comprising a packaged genome, wherein the packaged genome comprises a transgene. In particular, described herein are recombinant APMV (e.g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9). In another aspect, provided herein are methods for treating cancer comprising administering a recombinant APMV (e.g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9) to a subject in need thereof, wherein the recombinant APMV comprises a packaged genome comprising a transgene. In particular, provided herein are methods for treating cancer comprising administering a recombinant APMV-4 to a subject in need thereof, wherein the recombinant APMV-4 comprises a packaged genome comprising a transgene. In specific aspects, the use of APMV serotypes other than APMV-1 (such as described herein, in particular AMPV-4) to treat cancer is based, in part, on the similar or enhanced in vivo anti-tumor activities when compared to oncolytic NDV La Sota-L289A strain.
-76. (canceled)
A method for treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition comprising a naturally occurring avian paramyxovirus serotype 4 (APMV-4) or a recombinant APMV-4, wherein the APMV-4 or recombinant APMV-4 has an intracerebral pathogenicity index in day-old chicks of the Gallus gallus species of less than 0.7, and optionally wherein the subject is a human.
A recombinant avian paramyxovirus (APMV) comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a heterologous sequence, wherein the recombinant APMV has an intracerebral pathogenicity index in day-old chicks of the Gallus gallus species of less than 0.7, wherein the recombinant APMV comprises an APMV-4, APMV-8, APMV-9, APMV-6, or APMV-7 backbone, and optionally wherein the heterologous sequence encoded by the transgene is a cytokine or a tumor antigen, and optionally wherein the transgene is inserted between the APMV M and P transcription units of the packaged genome.
A method for treating cancer, comprising administering to a subject in need thereof a naturally occurring or recombinant avian paramyxovirus serotype 8 (APMV-8), a naturally occurring or recombinant APMV-9, a naturally occurring or recombinant APMV-7, or a naturally occurring or recombinant APMV-6, wherein the naturally occurring or recombinant APMV-8, naturally occurring or recombinant APMV-9, naturally occurring or recombinant APMV-7, or naturally occurring or recombinant APMV-6 has an intracerebral pathogenicity index in day-old chicks of the Gallus gallus species of less than 0.7.
Dependencies are inferred from the claim text.